++
+++
Essentials of Diagnosis
++
Develop secondary to portal hypertension
Found in 50% of patients with cirrhosis
Upper gastrointestinal (GI) bleeding develops in one-third
Diagnosis established by upper endoscopy
+++
General Considerations
++
Esophageal varices are dilated submucosal veins that develop in patients with underlying portal hypertension and may result in serious upper GI bleeding
Bleeding most commonly originates in the distal 5 cm of the esophagus
Bleeding from varices occurs in 30% of patients with esophageal varices
In the absence of any treatment, variceal bleeding spontaneously stops in about 50% of patients
Patients surviving this bleeding episode have a 60% chance of recurrent variceal bleeding, usually within the first 6 weeks
Factors that may portend an increased risk of bleeding include
Size of the varices
Presence at endoscopy of red wale markings on the varix
Severity of liver disease (as assessed by Child-Pugh score)
Active alcohol abuse—patients with cirrhosis who continue to drink have an extremely high risk of bleeding
++
Acute GI hemorrhage, usually severe, resulting in hypovolemia, postural vital signs, or shock
+++
Differential Diagnosis
++
Alcoholic gastritis
Mallory-Weiss syndrome
Portal hypertensive gastropathy
Peptic ulcer disease
Gastric or duodenal varices (rare)
Vascular ectasias (angiodysplasias), eg, idiopathic arteriovenous malformation, CREST syndrome, hereditary hemorrhagic telangiectasia
++
Complete blood count, platelet count, prothrombin time, INR
Serum liver enzymes
Creatinine, blood urea nitrogen
If bleeding, blood type and cross-match
+++
Diagnostic Procedures
++
++
Antibiotic prophylaxis reduces the risk of serious infection in hospitalized patients with cirrhosis and upper GI bleeding
Prophylactic administration of oral or intravenous antibiotics reduces the risk of serious infection to 10–20% as well as in-hospital mortality, especially in patients with Child-Pugh class C cirrhosis
Vasoactive agents
Octreotide, (50 mcg intravenous bolus followed by 50 mcg/h intravenously) infusion reduces splanchnic and hepatic blood flow and portal pressures
Terlipressin (1–2 mg intravenous every 4 hours; not available in the United States) causes significant reduction in portal and variceal pressures and, where available, may be preferred over octreotide
Combined vasoactive agents and endoscopic therapy (band ligation or sclerotherapy)
Vitamin K, 10 mg subcutaneously
Lactulose 30 mL orally every 2–3 hours until evacuation occurs, then reduced to 15–45 mL/h every 8–12 hours as needed to promote 2–3 bowel movements daily for hepatic encephalopathy
After bleeding ...